ADP ribose polymerase inhibitors for treating non-small cell lung cancer: new additions to the pharmacotherapeutic armamentarium-Reference-Cited by-同舟云学术

ADP ribose polymerase inhibitors for treating non-small cell lung cancer: new additions to the pharmacotherapeutic armamentarium

Published:2020-02-19 Issue:6 Volume:21 Page:679-686
ISSN:1465-6566
Container-title:Expert Opinion on Pharmacotherapy
language:en
Short-container-title:Expert Opinion on Pharmacotherapy

Author:

Rossi Giovanni¹²,Zullo Lodovica¹,Cerbone Luigi¹,Coco Simona¹,Longo Luca¹,Tagliamento Marco¹^ORCID,Dal Bello Maria Giovanna¹,Boccardo Simona¹,Alama Angela¹,Genova Carlo¹^ORCID

Affiliation:

1. Lung Cancer Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy

2. Department of Medical, Surgical and Experimental Sciences, University of Sassari, Italy

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14656566.2020.1724283

Reference69 articles.

1. New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs

2. Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer

3. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

4. Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers

5. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Niraparib for the Treatment of Metastatic NSCLC in a Patient With BRCA2 Germinal Mutation: A Case Report;Clinical Lung Cancer;2023-10

2. JASPER: Phase 2 trial of first‐line niraparib plus pembrolizumab in patients with advanced non–small cell lung cancer;Cancer;2021-09-03